Jagsonpal Pharmaceuticals share price today

Jagsonpal Pharmaceuticals Ltd's share price was ₹221.57 at the close on 4 November 2026. It has been rising for 20 weeks. That is 1.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹164 and ₹243, and at that close it sat 73% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Jagsonpal Pharmaceuticals Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 40 weeks in a row.

Over the last 11 years the share price moved +1,329% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

One change stood out: indian funds and insurers (DIIs) raised their stake for 6 quarters in a row.

1. Indian funds and insurers (DIIs) raised their stake for 6 quarters in a row

   From 0% to 1.6% of the company by the September 2026 quarter.

For July to September 2026 (the quarter ended 30 September 2026), Jagsonpal Pharmaceuticals reported revenue of ₹81.0 crore, up 9.5% from ₹74.0 crore a year earlier, and a profit of ₹13.0 crore, up 0.0% from ₹13.0 crore.

Jagsonpal Pharmaceuticals results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Jagsonpal Pharmaceuticals' management discussed these results on a call held on 29 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Jagsonpal Pharmaceuticals closed at ₹221.57 on 4 November 2026, up 2.6% from ₹216.04 a year earlier (7 November 2025) and up 211.8% over five years. Its highest weekly close since March 2016 was ₹304.48 on 29 November 2024.

Jagsonpal Pharmaceuticals share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Jagsonpal Pharmaceuticals closed at ₹221.57, up 2.2% on the week and down 4.3% on the month. 29 Oct 2026: Jagsonpal Pharmaceuticals held its results call for July to September 2026. Management guided: Quarterly revenue to cross ₹100 crore in October to December 2026.

Earlier

• Results for July to September 2026: Revenue up 9.5% and profit up 0.0% on a year earlier.
• 4 Sep 2026: ex-date for a dividend of ₹4 a share.
• Our read, 22 Aug 2026: Jagsonpal delivers cash conversion with a cash reserve of 170 crore rupees supporting capital returns. However, reported trailing EPS of 6.84 rupees is supported by peak operating margins of 20-21% compared with a 10-year normalized median of 9.8%.
• 8 Jan 2025: Share split: face value cut from ₹5 to ₹2 a share (ex-date).

Our read of the business

Jagsonpal delivers cash conversion with a cash reserve of 170 crore rupees supporting capital returns. However, reported trailing EPS of 6.84 rupees is supported by peak operating margins of 20-21% compared with a 10-year normalized median of 9.8%.

April to June 2026: Revenue grew 7.9% on a year earlier to 82 crore rupees as operating margin expanded to 21% alongside Equitas acquisition closing.

Our read after the April to June 2026 results, written 22 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

Jagsonpal Pharmaceuticals paid ₹4 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 1.81% at the ₹221.57 close on 4 November 2026. The last was a dividend of ₹4 a share, ex-date 4 September 2026.

Jagsonpal Pharmaceuticals dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Jagsonpal Pharmaceuticals Ltd paid out 62% of its profit as dividends in FY26, and it paid a dividend in 12 of its last 13 reported years. One of those years shows a negative figure because profit itself was negative.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 29 October 2026, Jagsonpal Pharmaceuticals' management guided: Quarterly revenue to cross ₹100 crore in October to December 2026.

“we are committed to this 500-crore vision, which we are sure to deliver with our current basket and without considering any further acquisitions in this 500-crore number”Amrut Medhekar, on the call for July to September 2026

What management guided

• Q3 growth in excess of 1.5 times expected industry growth.
• Consolidated operating margin above 22% in Q3, staying near that level except seasonally soft final quarter.
• Revenue ₹500 crore by FY28 purely organic on current basket without further acquisitions.
• Aequitas revenue ₹100 crore by FY28 reaffirmed with no change.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 29 October 2026.

What is changing at Jagsonpal Pharmaceuticals, from the latest results and calls: equitas institutional hospital expansion, core therapy premiumization and specialty mix and sales force productivity without headcount addition.

• Equitas Institutional Hospital Expansion. Acquisition of 85% equity in Equitas opens access to 1,000 corporate hospitals with an FY28-29 revenue goal of 100 crore rupees. ⚠ estimate
• Sales Force Productivity Without Headcount Addition. Operational restructuring focused on lifting monthly revenue per representative above 2.5 lakh rupees with zero new field additions planned. ✓ fact
• Balance Sheet Cash Deployment and Capital Distribution. Cash reserves of 170 crore rupees and 1.14x cash conversion support shareholder payouts and bolt-on acquisitions. ✓ fact

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Our read after the April to June 2026 results, written 22 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

Branded formulation revenue sustaining above 15% on a year earlier growth for three consecutive quarters with operating margins having above 20% on organic gross-margin expansion and monthly medical-representative productivity exceeding 2.5 lakh rupees.

Each change stops working if

• Equitas Institutional Hospital Expansion: Hospital procurement committees demand steep price concessions that compress gross margins below viable contribution thresholds.
• Core Therapy Premiumization and Specialty Mix: Volume contraction in mature legacy lines outpaces the revenue contribution from specialty brand additions.
• Sales Force Productivity Without Headcount Addition: Field attrition increases above 30% or doctor coverage frequency falls during territory re-alignment.

The main risks

• Hospital Procurement Price Erosion in Equitas: Institutional hospital customers negotiate aggressively, posing dilution risk to blended corporate margins. ⚠ estimate
• Management Guidance Credibility Deficit: History of downward guidance revisions and modifications to dividend terms introduces forecast execution discounts. ⚠ estimate
• Primary vs Secondary Sales Channel Divergence: Large gap between reported primary growth (9.0%) and secondary market data (18.9%) signals possible distributor inventory or timing distortion. ⚠ estimate
• Non-Operating Other Income Volatility: Periodic other-income items have historically distorted reported earnings comparisons. ⚠ estimate

Our read after the April to June 2026 results, written 22 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

When Jagsonpal Pharmaceuticals reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Print at flagged quarterly hurdle with margin accretion promised for that period.

Jagsonpal Pharmaceuticals is on 2 of our India lists: Dividend stocks and Pharma stocks.

Jagsonpal Pharmaceuticals Ltd earned ₹13.0 Cr of net profit in the Sep 2026 quarter, +0.0% on the same quarter a year earlier. Full-year FY26 profit was ₹43.0 Cr. Over 10 years profit has grown 30.5% a year on average. That is 16.0% of the quarter's revenue. The same quarter a year earlier earned ₹13.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹43.0 Cr (−21.8% on the year before).

Why profit moved: revenue changed +9.5% on a year earlier and the margin moved −1.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed −4.7% and revenue +6.1%. Profit is growing slower than sales: rising costs are taking part of the growth.

FY27-Q1. revenue ₹82 Cr and profit ₹13 Cr as reported.

FY27-Q2. revenue ₹81 Cr and profit ₹13 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Jagsonpal Pharmaceuticals Ltd reported ₹81.0 Cr of revenue in the Sep 2026 quarter, +9.5% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 10 years it has grown 7.2% a year on average. The last full year, FY26, came in at ₹287 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. Management completed an internal recalibration of its 1,000-person sales force across four divisions, stabilizing attrition and introducing structured training and incentive programs. Under a zero-new-addition model, FY27 volume expansion is intended to flow through productivity improvements of existing representatives, aiming for per-capita productivity above 2.5 lakh rupees per month from previous sub-peer levels.

The last four reported quarters add to ₹300 Cr.

FY26 revenue was ₹287 Cr, +6.7% on the year before.

Recent pace: the last four quarters grew +6.1% on average, against 7.2% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +6.0%, against +15.2% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −27.0%, against +38.4% a year (rolling over).

FY27-Q1. revenue ₹82 Cr and profit ₹13 Cr as reported.

FY27-Q2. revenue ₹81 Cr and profit ₹13 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Jagsonpal Pharmaceuticals Ltd's operating margin was 21.0% in the Sep 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between −9.0% and 20.0%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. The company is transitioning its product basket away from low-margin acute drugs toward specialty semi-chronic therapies where new-brand monthly sales run rates have nearly doubled. Key franchises such as Mantain (MAT near 46 crore rupees) and Indocap provide pricing support as 92% of the portfolio sits outside price control.

Why the margin moved: operating margin changed −1.5 percentage points on the year while gross margin changed +0.7 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

FY27-Q1. revenue ₹82 Cr and profit ₹13 Cr as reported.

FY27-Q2. revenue ₹81 Cr and profit ₹13 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Over the last 3 years, 114% of Jagsonpal Pharmaceuticals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹47.0 Cr of operating cash against ₹43.0 Cr of profit. After ₹0.0 Cr of spending on assets, ₹47.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Why this happened. The company reported 170 crore rupees in cash and liquid equivalents. Over the past four years, management said operating cash generation exceeded 250 crore rupees and was deployed toward acquisitions, dividends of over 40 crore rupees, and a 40 crore rupee share buyback. This liquidity provides self-funding capacity for bolt-on brand acquisitions, subject to acquisition valuation and integration discipline.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 114% of profit came in as cash: the cash cycle got 44 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 4.2× depreciation over three years. The next section checks what that spending is building.

Jagsonpal Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 33 days in FY26, down from 77 days in FY21. It spent ₹80.0 Cr on assets over the last 3 years. Customers take 22 days to pay, and stock sits for 51 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Why this happened. Jagsonpal acquired 85% of Equitas Healthcare for 20.8 crore rupees, adding an ICU-focused branded injectable portfolio with FY26 revenue of 53 crore rupees. The acquisition provides almost 49 institutional representatives and relationships with 4,000 specialists across major hospital chains including Max, Manipal, Medanta, and Cloud9. Management goals scaling Equitas to 100 crore rupees revenue and upward of 10 crore rupees EBITDA within 30 months by cross-sales core brands like Indocap and Mantain.

At FY26 sales of ₹287 Cr, each day of that cycle ties up about ₹0.8 Cr, so roughly ₹26.0 Cr is tied up in the business at any time.

FY26: customers took 22 days to pay and stock sat for 51 days, about 1.7 months of sales sitting as stock, for a full cycle of 33 days, shorter than FY21's 77.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 51 days. Customers pay about 22 days after that. Suppliers are paid at 40 days. Together that makes the 33-day cycle.

Spending on assets: ₹80.0 Cr over the last 3 years, against ₹19.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Jagsonpal Pharmaceuticals Ltd's P/E is 31.0×, in the middle of its own history: higher than 48% of past readings. Its usual P/E (the middle reading) is 31.4×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹6.86.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.